type 2 diabetes mellitus with diabetic amyotrophy

🔥+ type 2 diabetes mellitus with diabetic amyotrophy 03 Jul 2020 two diagnoses or a diagnosis with an associated secondary process ... Combination codes for diabetes mellitus include the type, the body system affected, and ...

type 2 diabetes mellitus with diabetic amyotrophy ... deconstructs the differences between type 1 and type 2 diabetes, and how you can improve your overall health while living with the disease.

sugar mountain movie spoilers
Skip to main content

Main menu

Search

Section I: Diabetes-What Is New in for 1 last update 03 Jul 2020 the Management and Understanding of the Disease?Section I: Diabetes-What Is New in the Management and Understanding of the Disease?

From metabolic stress to therapy

  1. Marc Y. Donath, MD,
  2. Desiree M. Schumann, PHD,
  3. Mirjam Faulenbach, MD,
  4. Helga Ellingsgaard, PHD,
  5. Aurel Perren, MD and
  6. Jan A. Ehses, PHD
  1. From the Clinic of Endocrinology and Diabetes, Department of Pathology, University Hospital Zurich, Zurich, Switzerland
  1. Address correspondence and reprint requests to Marc Y. Donath, MD, Clinic of Endocrinology and Diabetes, Department of Medicine, University Hospital, CH-8091 Zurich, Switzerland. E-mail: marc.donath{at}usz.ch
type 2 diabetes mellitus with diabetic amyotrophy onset age (👍 need insulin) | type 2 diabetes mellitus with diabetic amyotrophy nursinghow to type 2 diabetes mellitus with diabetic amyotrophy for Diabetes for 1 last update 03 Jul 2020 Care Diabetes Care 2008 Feb; 31(Supplement 2): S161-S164. https://doi.org/10.2337/dc08-s243

Abstract

Decreases in both mass and secretory function of insulin-producing β-cells contribute to the pathophysiology of type 2 diabetes. The histology of islets from patients with type 2 diabetes displays an inflammatory process characterized by the presence of cytokines, apoptotic cells, immune cell infiltration, amyloid deposits, and eventually fibrosis. This inflammatory process is probably the combined consequence of dyslipidemia, hyperglycemia, and increased circulating adipokines. Therefore, modulation of intra-islet inflammatory mediators, in particular interleukin-1β, appears as a promising therapeutic approach.

Inflammation is defined as the local response to tissue injury. It is characterized by immune cell invasion and local release of cytokines and chemokines and is sometimes accompanied by functional or structural damage of the invaded tissue. It is not in itself a disease, but a manifestation of disease. Inflammation has beneficial effects such as preventing spread of infections or promoting regeneration. Equally, it may exacerbate disease by tissue destruction due to inflammatory mediators, reactive oxygen species, and complement components. In this review, we propose to revisit the pathology of islet failure in type 2 diabetes and highlight evidence that this includes an inflammatory process in response to metabolic stress.

GLUCOSE-INDUCED β-CELL PRODUCTION OF INTERLEUKIN-1β: FROM ADAPTATION TO FAILURE—

Glucose is the main physiological regulator of insulin secretion. In addition to this acute effect, glucose also regulates the long-term adaptation of insulin production by affecting β-cell turnover. Indeed, short-term exposure of β-cells to increasing glucose concentrations induces proliferation (13). However, in Psammomys obesus, an animal model of type 2 diabetes, and in humans, the proliferative capacity of the β-cell is suppressed after a prolonged exposure to increased glucose concentrations (2,3). Moreover, elevated glucose concentrations induce β-cell apoptosis in cultured islets from diabetes-prone Psammomys obesus (2) and from humans (3,4).

Interleukin (IL)-1β is a pro-inflammatory cytokine acting during the autoimmune process of type 1 the 1 last update 03 Jul 2020 diabetes (5). IL-1β inhibits β-cell function and promotes Fas-triggered apoptosis in part by activating the transcription factor nuclear factor (NF)-κB. We tested the hypothesis that IL-1β may mediate the deleterious effects of high glucose on human β-cells (6). In vitro exposure of islets from nondiabetic organ donors to high glucose levels resulted in increased production and release of IL-1β, followed by NF-κB activation, Fas upregulation, DNA fragmentation, and impaired β-cell secretory function. The IL-1 receptor antagonist (IL-1Ra) protected cultured human islets from these deleterious effects. β-Cells themselves were identified as the islet cellular source of glucose-induced IL-1β. In vivo, IL-1β–producing β-cells were observed in pancreatic sections of type 2 diabetic patients but not in nondiabetic control subjects. These findings implicate an inflammatory process in the pathogenesis of glucotoxicity in type 2 diabetes and identify the IL-1β pathway as a target to preserve β-cell mass and function in this condition.Interleukin (IL)-1β is a pro-inflammatory cytokine acting during the autoimmune process of type 1 diabetes (5). IL-1β inhibits β-cell function and promotes Fas-triggered apoptosis in part by activating the transcription factor nuclear factor (NF)-κB. We tested the hypothesis that IL-1β may mediate the deleterious effects of high glucose on human β-cells (6). In vitro exposure of islets from nondiabetic organ donors to high glucose levels resulted in increased production and release of IL-1β, followed by NF-κB activation, Fas upregulation, DNA fragmentation, and impaired β-cell secretory function. The IL-1 receptor antagonist (IL-1Ra) protected cultured human islets from these deleterious effects. β-Cells themselves were identified as the islet cellular source of glucose-induced IL-1β. In vivo, IL-1β–producing β-cells were observed in pancreatic sections of type 2 diabetic patients but not in nondiabetic control subjects. These findings implicate an inflammatory process in the pathogenesis of glucotoxicity in type 2 diabetes and identify the IL-1β pathway as a target to preserve β-cell mass and function in this condition.

Recently, the role of IL-1β in type 2 diabetes has been challenged based on findings in islets isolated from patients with this condition (7). Unfortunately, these islets were placed in medium containing 5.5 mmol/l glucose for 3–4 days before experimentation. The reversibility of glucotoxicity is well documented (8) as well as the reversibility of glucose-induced IL-1β expression (6). It is therefore not surprising that increased levels of IL-1β were not detectable in these islets. Furthermore, there are numerous methodological differences, including the lack of use of extracellular matrix and the low number of organ donor samples that may account for some reported differences. Finally, a recent gene array analysis of near-pure populations of β-cells obtained by laser capture dissection displayed increased IL-1β mRNA expression in samples obtained from patients with type 2 diabetes (9).

Based on these findings, we conducted a clinical trial of IL-1 receptor antagonism in type 2 diabetes (10). The primary end-point, glycated hemoglobin, was significantly lower in IL-1Ra–treated versus placebo-treated patients, associated with enhanced insulin secretion. This study is proof of principle that antagonism of IL-1 has therapeutic potential in the treatment of diabetes, and supports the concept that islet inflammation is present and detrimental to islet function in type 2 diabetes.

DYSLIPIDEMIA, LEPTIN, AND CIRCULATING CYTOKINES: LINKING OBESITY TO β-CELL FAILURE—

Obesity is the main risk factor for the development of diabetes. It is often part of the metabolic syndrome and is accompanied by dyslipidemia and increased circulating leptin and cytokine levels. All of these factors have been shown to modulate β-cell function and survival. The influence of dyslipidemia on the β-cells of an individual will depend on his or her specific lipid profile. Whereas some free fatty acids and lipoproteins have been shown to be pro-apoptotic for the β-cell, others are protective. For example, long-term exposure of β-cells to saturated fatty acids such as palmitate appears highly toxic, whereas monounsaturated fatty acids such as oleate protect against both palmitate- and glucose-induced β-cell apoptosis (11,12). It is of interest to note that similar toxic effects are also observed in non–β-cells such as cardiac cells (13). These effects are paralleled by effects on β-cell function (i.e., saturated fatty acids are detrimental, whereas monounsaturated fatty acids are protective). Lipoproteins may also affect β-cell survival and function in a similar way, whereby VLDL and LDL are pro-apoptotic, while HDL is protective (1416). These lipotoxic effects may also be influenced by the prevailing glycemia (17,18).

Leptin was initially identified as an adipocyte-derived satiety factor. Recently, leptin has also been considered as a proinflammatory cytokine because of its structural similarity with other cytokines and its receptor-induced signaling pathways (19). Interestingly, leptin accelerates autoimmune diabetes in NOD mice (20), providing an additional link between type 1 and type 2 diabetes (21). Of note, leptin also promotes other autoimmune diseases, including inflammatory bowel disease (22), multiple sclerosis (23), and rheumatoid arthritis (19). We have found that leptin, in addition to its established negative effect on insulin secretion (24,25), induces β-cell apoptosis via increasing release of IL-1β and decreasing release of IL-1Ra in human islets (26). Other cytokines released by adipocytes, including tumor necrosis factor-α and IL-6, may also modulate β-cell survival, although it is unclear if the amount released into the circulation is sufficient to affect β-cells (27,28). Furthermore, it may well be that these cytokines are only effective in the presence of other cytokines. Details regarding how all the above-mentioned factors affect β-cell secretory function have been reviewed elsewhere (27).

IMMUNE CELL INFILTRATION IN ISLETS FROM TYPE 2 DIABETIC PATIENTS—

Pancreatic islets from type 2 diabetic patients are known to present with amyloid deposits, fibrosis, and increased cell death (2931). All of these hallmarks are associated with an inflammatory response. Indeed, given that pancreatic β-cell mass is now known to decrease in type 2 diabetes (3133), the immune system is most likely associated with the removal of these apoptotic or necrotic endocrine cells. However, before massive cell death and immune infiltration, pancreatic islets may respond to metabolic stress by producing inflammatory factors. As mentioned above, the human pancreatic β-cell produces increased IL-1β in response to glucotoxicity (6). Various other inflammatory factors and nutrients have also been shown to induce an islet inflammatory response in vitro (3436). In support of this hypothesis, there is now evidence that islet macrophage infiltration occurs in the GK rat (37), the high-energy diet–fed mouse, the db/db mouse, and human type 2 diabetes before the onset or independently of significant islet cell death (Fig. 1) (38). Given that type 2 diabetes is characterized by hyperglycemia, dyslipidemia, and increased circulating inflammatory factors (so- called low-grade inflammation), increased cellular stress may be critical in precipitating islet inflammation in vivo.

type 2 diabetes mellitus with diabetic amyotrophy explained (🔥 mellitus nature journal) | type 2 diabetes mellitus with diabetic amyotrophy range charthow to type 2 diabetes mellitus with diabetic amyotrophy for Figure 1—

Increased number of islet macrophages in type 2 diabetic islets. Pancreatic section from a nondiabetic patient (A) and a patient with type 2 diabetes (B) displaying increased numbers of islet-associated macrophages detected by double immunostaining for CD68 in brown (arrows) and insulin in red. For detailed methods and quantification, see Ehses et al. (38).

ISLET INFLAMMATION: FROM PHYSIOLOGY TO FAILURE—

type 2 diabetes mellitus with diabetic amyotrophy dinner menu (🔴 Treatments) | type 2 diabetes mellitus with diabetic amyotrophy menuhow to type 2 diabetes mellitus with diabetic amyotrophy for The impact of islet-derived inflammatory factors and islet inflammation on β-cell function and mass may be both beneficial and/or deleterious. Low concentrations of IL-1β promote β-cell function and survival (39). Other chronically elevated cytokines and chemokines in obesity and type 2 diabetes, such as IL-6, IL-8, and monocyte chemoattractant protein (MCP)-1, may also play a role in pancreatic islet adaptation (28,40,41). Indeed, the immune system is classically involved in both adaptation and repair; however, if the 1 last update 03 Jul 2020 this response becomes prolonged, it may become deleterious to organ function. All this emerging evidence reinforces the paradigm that islet inflammation is involved in the regulation of β-cell function and survival in type 2 diabetes.The impact of islet-derived inflammatory factors and islet inflammation on β-cell function and mass may be both beneficial and/or deleterious. Low concentrations of IL-1β promote β-cell function and survival (39). Other chronically elevated cytokines and chemokines in obesity and type 2 diabetes, such as IL-6, IL-8, and monocyte chemoattractant protein (MCP)-1, may also play a role in pancreatic islet adaptation (28,40,41). Indeed, the immune system is classically involved in both adaptation and repair; however, if this response becomes prolonged, it may become deleterious to organ function. All this emerging evidence reinforces the paradigm that islet inflammation is involved in the regulation of β-cell function and survival in type 2 diabetes.

ANTI-DIABETIC DRUGS AND ISLET INFLAMMATION—

Understanding that islet inflammation is an important factor in the pathogenesis of type 2 diabetes raises a concern regarding the application of drugs potentially harmful to the remaining β-cells. Conversely, protection of β-cells from death presents itself as a new therapeutic target. In this context, modulation of the β-cell ATP-sensitive K+ (KATP) channels (octamers composed of four inwardly rectifying K+-channels [Kir 6.2] and four sulfonylurea receptors [SUR1]) appears particularly interesting. Indeed, closure of the KATP channels by the sulfonylureas tolbutamide and glibenclamide may induce Ca2+-dependent β-cell apoptosis in rodent and human islets (4244). This effect was observed only in vitro and not consistently (45). However, in an important recent clinical study comparing insulin and sulfonylurea treatment of type 2 diabetes, it was shown that treatment with insulin preserved β-cell function more effectively than glibenclamide (46). It remains to be established whether it is the beneficial effects of insulin per se or the possible β-cell toxicity of glibenclamide that accounts for this observation. Whereas a deterioration of insulin secretion was seen in patients treated with sulfonylureas in the U.K. Prospective Diabetes Study, those treated with insulin were not evaluated in this regard (47). Given the possible deleterious effect of some sulfonylureas, alternatives to these as well as alternative insulin secretagogues may have to be considered. When applied at the concentration of their respective circulating half-lives in vitro, repaglinide and nateglinide do not appear to have an apoptotic effect on human islets (44). In contrast to sulfonylureas, KATP channel openers may exert protective effects on β-cells (48,49). In 1976, Greenwood et al. (50) were the first to report an improvement in insulin secretion after administration of diazoxide for 7 days to diabetic subjects. Similar protective effects were observed more recently in patients classified with type 1 and type 2 diabetes (51,52). Finally, other antidiabetic drugs that have emerged as putative protectors of β-cells include thiazolidinediones, GLP-1 analogs, insulin (44,5355), and last but not least, IL-1Ra (10).

Footnotes

  • M.Y.D. is listed as the inventor on a patent (WO6709) filed in 2003 for the use of an interleukin-1 receptor antagonist for the treatment of or prophylaxis against type 2 diabetes. The patent is owned by the University of Zurich, and M.Y.D. has no financial interest in the patent. No other potential conflict of interest relevant to this article was reported.

    This article is based on a presentation at the 1st World Congress of Controversies in Diabetes, Obesity and Hypertension (CODHy). The Congress and the publication of this article were made possible by unrestricted educational grants from MSD, Roche, sanofi-aventis, Novo Nordisk, Medtronic, LifeScan, World Wide, Eli Lilly, Keryx, Abbott, Novartis, Pfizer, Generx Biotechnology, Schering, and Johnson & Johnson.

  • DIABETES CARE

References

  1. Chick WL, Like AA: Studies in the diabetic mutant mouse. 3 Physiological factors associated with alterations in beta cell proliferation. Diabetologia 6:243–251, the 1 last update 03 Jul 2020 19701970
  2. Donath MY, Gross DJ, Cerasi E, Kaiser N: Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 48:738–744, 1999
  3. Maedler K, Spinas GA, Lehmann R, Sergeev P, Weber M, Fontana A, Kaiser N, Donath MY: Glucose induces beta-cell apoptosis via upregulation of the Fas-receptor in human islets. Diabetes 50:type 2 diabetes mellitus with diabetic amyotrophy overview (🔥 exercise) | type 2 diabetes mellitus with diabetic amyotrophy kidshealthhow to type 2 diabetes mellitus with diabetic amyotrophy for the 1 last update 03 Jul 2020 16831683–1690, 2001
  4. Federici M, Hribal M, Perego L, Ranalli M, Caradonna Z, Perego C, Usellini L, Nano R, Bonini P, Bertuzzi F, Marlier LN, Davalli AM, Carandente O, Pontiroli AE, Melino G, Marchetti P, Lauro R, Sesti G, Folli F: High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 50: for 1 last update 03 Jul 2020 12901290–1301, 2001
  5. Mandrup-Poulsen T: The role of interleukin-1 in the pathogenesis of IDDM. the 1 last update 03 Jul 2020 DiabetologiaDiabetologia type 2 diabetes mellitus with diabetic amyotrophy straight talk (🔴 video) | type 2 diabetes mellitus with diabetic amyotrophy treatments google searchhow to type 2 diabetes mellitus with diabetic amyotrophy for 39:1005–1029, 1996
  6. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY: Glucose-induced beta-cell production of interleukin-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110:851–860, type 2 diabetes mellitus with diabetic amyotrophy weight gain (🔥 long term effects) | type 2 diabetes mellitus with diabetic amyotrophy e119how to type 2 diabetes mellitus with diabetic amyotrophy for 2002
  7. Welsh N, Cnop M, Kharroubi I, Bugliani M, Lupi R, Marchetti P, Eizirik DL: Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets? Diabetes 54:3238–3244, 2005
  8. Thorens B, Wu YJ, Leahy JL, Weir GC: The loss of GLUT2 expression by glucose-unresponsive beta cells of db/db mice is reversible and is induced by the diabetic environment. J Clin Invest 90:77–85, 1992
  9. Boni-Schnetzler M, Marselli L, Ehses JA, Weir GC, Donath MY: IL-1beta expression is induced by glucose and IL-1beta auto-stimulation, and increased in beta cells of type 2 diabetics (Abstract). Diabetes 56 (Suppl. 1): for 1 last update 03 Jul 2020 A413A413, 2007
  10. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY: Interleukin-1 receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526, 2007
  11. Maedler K, Oberholzer J, Bucher P, Spinas GA, Donath MY: Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes type 2 diabetes mellitus with diabetic amyotrophy test kit (🔴 occur) | type 2 diabetes mellitus with diabetic amyotrophy grocery listhow to type 2 diabetes mellitus with diabetic amyotrophy for 52:726–733, type 2 diabetes mellitus with diabetic amyotrophy gout (🔥 feet) | type 2 diabetes mellitus with diabetic amyotrophy vitamind3how to type 2 diabetes mellitus with diabetic amyotrophy for 2003
  12. Maedler K, Spinas GA, Dyntar D, Moritz W, Kaiser N, Donath MY: Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function. Diabetes 50:69–76, 2001
  13. Dyntar D, Eppenberger-Eberhardt M, Maedler K, Pruschy M, Eppenberger H, Spinas GA, Donath MY: Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. the 1 last update 03 Jul 2020 DiabetesDiabetes 50:2105–2113, 2001
  14. Cnop M, Hannaert JC, Grupping AY, Pipeleers DG: Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology type 2 diabetes mellitus with diabetic amyotrophy cause high blood pressure (☑ origin) | type 2 diabetes mellitus with diabetic amyotrophy occurs whenhow to type 2 diabetes mellitus with diabetic amyotrophy for 143:3449–3453, 2002
  15. Roehrich ME, Mooser V, Lenain V, Herz J, Nimpf J, Azhar S, Bideau M, Capponi A, Nicod P, Haefliger JA, Waeber G: Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem 278:18368–18375, for 1 last update 03 Jul 2020 20032003
  16. Rütti S, Ehses JA, Rohrer L, Prazak R, von Eckardstein A, Donath MY: High density lipoprotein protects human and mouse pancreatic islets from high glucose and interleukin-1 beta induced apoptosis (Abstract). Diabetes 56 (Suppl. 1):A27, 2007
  17. El-Assaad W, Buteau J, Peyot ML, Nolan C, Roduit R, Hardy S, Joly E, Dbaibo G, Rosenberg L, Prentki M: Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 144:4154–4163, 2003
  18. Poitout V, Robertson RP: Minireview: secondary beta-cell failure in type 2 diabetes: a convergence of glucotoxicity and lipotoxicity. Endocrinology 143:339–342, 2002
  19. Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gomez-Reino JJ, Gualillo O: Leptin, from fat to inflammation: old questions and new insights. FEBS for 1 last update 03 Jul 2020 LettFEBS Lett 579:295–301, 2005
  20. Matarese G, Sanna V, Lechler RI, Sarvetnick N, Fontana S, Zappacosta S, La Cava A: Leptin accelerates autoimmune diabetes in female NOD mice. Diabetes 51:1356–1361, for 1 last update 03 Jul 2020 20022002
  21. Donath MY, Ehses JA: Type 1, type 1.5, and type 2 diabetes: NOD the diabetes we thought it was. Proc Natl Acad Sci U S A 103:type 2 diabetes mellitus with diabetic amyotrophy symptoms in women (⭐️ autoimmune) | type 2 diabetes mellitus with diabetic amyotrophy food charthow to type 2 diabetes mellitus with diabetic amyotrophy for 12217–12218, type 2 diabetes mellitus with diabetic amyotrophy questionnaire (👍 with diet) | type 2 diabetes mellitus with diabetic amyotrophy beta cellshow to type 2 diabetes mellitus with diabetic amyotrophy for 2006
  22. Barbier M, Cherbut C, Aube AC, Blottiere HM, Galmiche JP: Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats. Gut type 2 diabetes mellitus with diabetic amyotrophy use insulin (🔴 australia) | type 2 diabetes mellitus with diabetic amyotrophy and exercisehow to type 2 diabetes mellitus with diabetic amyotrophy for 43:783–790, 1998
  23. Sanna V, Di Giacomo A, La Cava A, Lechler RI, Fontana S, Zappacosta S, Matarese G: Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest for 1 last update 03 Jul 2020 111111:241–250, 2003
  24. Kieffer TJ, Habener JF: The adipoinsular axis: effects of leptin on pancreatic beta-cells. Am J Physiol Endocrinol Metab 278:E1–E14, the 1 last update 03 Jul 2020 20002000
  25. Roduit R, Thorens B: Inhibition of glucose-induced insulin secretion by long-term preexposure of pancreatic islets to leptin. FEBS Lett 415: for 1 last update 03 Jul 2020 179179–182, 1997
  26. Maedler K, Sergeev P, Ehses JA, Mathe Z, Bosco D, Berney T, Dayer JM, Reinecke M, Halban PA, Donath MY: Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci U S A 101:8138–8143, 2004
  27. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T: Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med 81:455–470, 2003
  28. Ellingsgaard H, Ehses JA, van Lommel L, Schuit FC, Donath MY: IL-6 regulates alpha-cell mass and function. Diabetologia 49 (Suppl 1):282–283, 2006
  29. Hull RL, Westermark GT, Westermark P, Kahn SE: Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 89:3629–3643, 2004
  30. Marzban L, Park K, Verchere CB: Islet amyloid polypeptide and type 2 diabetes. Exp Gerontol 38:type 2 diabetes mellitus with diabetic amyotrophy questions for dr (☑ blood sugar chart) | type 2 diabetes mellitus with diabetic amyotrophy long term effectshow to type 2 diabetes mellitus with diabetic amyotrophy for 347–351, 2003
  31. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S: Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 45:85–96, type 2 diabetes mellitus with diabetic amyotrophy without medication (🔴 test) | type 2 diabetes mellitus with diabetic amyotrophy treatmenthow to type 2 diabetes mellitus with diabetic amyotrophy for for 1 last update 03 Jul 2020 20022002
  32. Yoon KH, Ko SH, Cho JH, Lee JM, Ahn YB, Song KH, Yoo SJ, Kang MI, Cha BY, Lee KW, Son HY, Kang SK, Kim HS, Lee IK, Bonner-Weir S: Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 88:2300–2308, for 1 last update 03 Jul 2020 20032003
  33. Arnush M, Heitmeier MR, Scarim AL, Marino MH, Manning PT, Corbett JA: IL-1 produced and released endogenously within human islets inhibits beta cell function. J the 1 last update 03 Jul 2020 Clin InvestJ Clin Invest 102: for 1 last update 03 Jul 2020 516516–526, 1998
  34. Busch AK, Cordery D, Denyer GS, Biden TJ: Expression profiling of palmitate- and oleate-regulated genes provides novel insights into the effects of chronic lipid exposure on pancreatic beta-cell function. Diabetes 51:977–987, 2002
  35. Homo-Delarche F, Calderari S, Irminger JC, Gangnerau MN, Coulaud J, Rickenbach K, Dolz M, Halban P, Portha B, Serradas P: Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes 55:1625–1633, 2006
  36. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, Gueripel X, Ellingsgaard H, Schneider MKJ, Biollaz G, Fontana A, Reinecke M, Homo-Delarche F, Donath MY: Increased number is islet associated macrophages in type 2 diabetes. Diabetes 56:2356–2370, 2007
  37. Maedler K, Schumann DM, Sauter N, Ellingsgaard H, Bosco D, Baertschiger R, Iwakura Y, Oberholzer J, Wollheim CB, Gauthier BR, Donath MY: Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets. Diabetes type 2 diabetes mellitus with diabetic amyotrophy treatment studies (⭐️ and covid-19) | type 2 diabetes mellitus with diabetic amyotrophy treatments and regimentshow to type 2 diabetes mellitus with diabetic amyotrophy for 55:type 2 diabetes mellitus with diabetic amyotrophy virus (🔴 symptoms mayo clinic) | type 2 diabetes mellitus with diabetic amyotrophy grocery listhow to type 2 diabetes mellitus with diabetic amyotrophy for 2713–2722, 2006
  38. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest type 2 diabetes mellitus with diabetic amyotrophy questionnaire (⭐️ recipes) | type 2 diabetes mellitus with diabetic amyotrophy oatmealhow to type 2 diabetes mellitus with diabetic amyotrophy for 115: the 1 last update 03 Jul 2020 11111111–1119, 2005
  39. Schumann DM, Maedler K, Franklin I, Konrad D, Storling J, Böni-Schnetzler, Gjinovci A, Kurrer MO, Gauthier BR, Bosco D, Andres A, Berney T, Greter M, Bercher B, Chervonsky AV, Halban P, Mandrup-Poulsen T, Wollheim CB, Donath MY: The Fas pathway is involved in beta-cell secretory function. Proc Natl Acad Sci U S A 104:type 2 diabetes mellitus with diabetic amyotrophy treatments and regiments (🔥 info) | type 2 diabetes mellitus with diabetic amyotrophy life expectancyhow to type 2 diabetes mellitus with diabetic amyotrophy for 2861–2866, 2007
  40. Efanova IB, Zaitsev SV, Zhivotovsky B, Kohler M, Efendic S, Orrenius S, Berggren PO: Glucose and tolbutamide induce apoptosis in pancreatic beta-cells: a process dependent on intracellular Ca2+ concentration. J Biol Chem 273:33501–33507, 1998
  41. Iwakura T, Fujimoto S, Kagimoto S, Inada A, Kubota A, Someya Y, Ihara Y, Yamada Y, Seino Y: Sustained enhancement of Ca(2+) influx by glibenclamide induces apoptosis in RINm5F cells. Biochem Biophys Res Commun 271:422–428, 2000
  42. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY: Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90:501–506, 2005
  43. Del Guerra S, Marselli L, Lupi R, Boggi U, Mosca F, Benzi L, Del Prato S, Marchetti P: Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications the 1 last update 03 Jul 2020 1919:60–64, 2005
  44. Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E, Steen L, Westermark G, Westermark P, Orn T, Grill V: Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26:2231–2237, 2003
  45. U.K. Prospective Diabetes Study 16: Overview of 6 years’ therapy of type II diabetes: a progressive disease: U.K. Prospective Diabetes Study Group. Diabetes 44:1249–1258, 1995
  46. Maedler K, Storling J, Sturis J, Zuellig RA, Spinas GA, Arkhammar PO, Mandrup-Poulsen T, Donath MY: Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes 53:1706–1713, 2004
  47. Ritzel RA, Hansen JB, Veldhuis JD, Butler PC: Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose. J Clin Endocrinol Metab 89:795–805, 2004
  48. Bjork E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson FA: Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 45:1427–1430, 1996
  49. Guldstrand M, Grill V, Bjorklund A, Lins PE, Adamson U: Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes. Diabetes Metab 28:448–456, 2002
  50. Drucker DJ: Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology the 1 last update 03 Jul 2020 144144:5145–5148, 2003
  51. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ: Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem the 1 last update 03 Jul 2020 278278:471–478, type 2 diabetes mellitus with diabetic amyotrophy exhaustion (⭐️ kidney failure) | type 2 diabetes mellitus with diabetic amyotrophy with chronic kidney diseasehow to type 2 diabetes mellitus with diabetic amyotrophy for 2003
  52. Zeender E, Maedler K, Bosco D, Berney T, Donath MY, Halban PA: Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab 89:5059–5066, the 1 last update 03 Jul 2020 20042004
View Abstract

In this Issue

February 2008, 31(Supplement 2)
Sign In to Email Alerts with your Email Address

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Islet Inflammation in Type 2 Diabetes
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Islet Inflammation in Type 2 Diabetes
type 2 diabetes mellitus with diabetic amyotrophy need insulin (👍 guidelines 2020) | type 2 diabetes mellitus with diabetic amyotrophy oral medicationshow to type 2 diabetes mellitus with diabetic amyotrophy for Marc Y. Donath, Desiree the 1 last update 03 Jul 2020 M.Desiree M. Schumann, Mirjam type 2 diabetes mellitus with diabetic amyotrophy hereditary (🔥 quora) | type 2 diabetes mellitus with diabetic amyotrophy namehow to type 2 diabetes mellitus with diabetic amyotrophy for Faulenbach, Helga Ellingsgaard, Aurel Perren, Jan A. Ehses
Diabetes Care Feb 2008, 31 (Supplement 2) type 2 diabetes mellitus with diabetic amyotrophy nature (👍 symptoms nhs) | type 2 diabetes mellitus with diabetic amyotrophy undiagnosedhow to type 2 diabetes mellitus with diabetic amyotrophy for S161-S164; DOI: 10.2337/dc08-s243

Islet Inflammation in Type 2 Diabetes
Marc Y. Donath, type 2 diabetes mellitus with diabetic amyotrophy ncbi (☑ wild rice) | type 2 diabetes mellitus with diabetic amyotrophy lunchhow to type 2 diabetes mellitus with diabetic amyotrophy for Desiree M. Schumann, type 2 diabetes mellitus with diabetic amyotrophy cause hypertension (🔴 natural) | type 2 diabetes mellitus with diabetic amyotrophy statistics australiahow to type 2 diabetes mellitus with diabetic amyotrophy for the 1 last update 03 Jul 2020 MirjamMirjam Faulenbach, Helga Ellingsgaard, Aurel type 2 diabetes mellitus with diabetic amyotrophy nature (👍 obesity) | type 2 diabetes mellitus with diabetic amyotrophy fruits to eathow to type 2 diabetes mellitus with diabetic amyotrophy for Perren, Jan A. Ehses
Diabetes Care Feb 2008, 31 (Supplement 2) S161-S164; type 2 diabetes mellitus with diabetic amyotrophy treatment (🔴 and insulin) | type 2 diabetes mellitus with diabetic amyotrophy journalhow to type 2 diabetes mellitus with diabetic amyotrophy for DOI: 10.2337/dc08-s243

Related Articles

Cited By...

More in this TOC Section

type 2 diabetes mellitus with diabetic amyotrophy oral medications (☑ lab values) | type 2 diabetes mellitus with diabetic amyotrophy questions and answershow to type 2 diabetes mellitus with diabetic amyotrophy for Similar Articles